Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GH · against 93 other Healthcare companies of similar size
Ranked #85 of 94 · scores higher than 0% of peers
Bars: peers in each 10-point band of the valuation score10 peers with a valuation score of 0–9, including GH · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | GH | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 92 reported | -2.0% | 3.1% | 7% | 30% | |
| EBITDA yieldHigher is better · 94 reported | -1.8% | 5.4% | 6% | 50% | |
| Free cash flow yieldHigher is better · 59 reported | -1.0% | 3.8% | 10% | 20% | |
| Book yieldHigher is better · 88 reported | -1.0% | 21.6% | 1% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.5B USD | 95 | 60 | |
| 2 | 68.0B BRL (≈$12.2B) | 94 | 67 | |
| 3 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 4 | 14.4B USD | 92 | 71 | |
| 5 | 66.0B BRL (≈$11.9B) | 89 | 55 | |
| 84 | 16.5B USD | 36 | 37 | |
| 85 | 14.5B USD | 8 | 30 | |
| 85 | 21.8B USD | 8 | 32 | |
| 85 | 33.3B USD | 8 | 24 | |
| 85 | 23.5B USD | 8 | 27 | |
| 85 | 13.7B USD | 8 | 45 | |
| 85 | 22.8B USD | 8 | 38 | |
| 85 | 26.0B USD | 8 | 28 | |
| 85 | 41.6B USD | 8 | 34 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score